Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol

Kausik K. Ray, R. Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A. Leiter, Frederick J. Raal, Jenna A. Bisch, Tara Richardson, Mark Jaros, Peter L.J. Wijngaard, John J.P. Kastelein

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

BACKGROUND Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. RESULTS A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (SD) LDL cholesterol levels at baseline were 104.738.3 mg per deciliter (2.710.99 mmol per liter) and 105.539.1 mg per deciliter (2.731.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. CONCLUSIONS Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo.

Original languageEnglish (US)
Pages (from-to)1507-1519
Number of pages13
JournalNew England Journal of Medicine
Volume382
Issue number16
DOIs
StatePublished - Apr 16 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol'. Together they form a unique fingerprint.

  • Cite this

    Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., & Kastelein, J. J. P. (2020). Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New England Journal of Medicine, 382(16), 1507-1519. https://doi.org/10.1056/NEJMoa1912387